Skip to main content

Granulomatosis With Polyangiitis

2
Pipeline Programs
5
Companies
6
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 4 programs with unclassified modality

On Market (1)

Approved therapies currently available

TAVNEOSApproved
avacopan
Unknown Company
Complement 5a Receptor Antagonist [EPC]oral2021
34M Part D

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
avacopanPhase 2/32 trials
Active Trials
NCT06468826Completed13Est. Oct 2024
NCT06207682Completed32Est. Aug 2022
Airway Therapeutics
Airway TherapeuticsGA - Marietta
2 programs
Airway assessmentN/A1 trial
Granulomatosis With Polyangiitis Natural History StudyN/A
Active Trials
NCT03182049Withdrawn0Est. May 2023
Genentech
GenentechCA - Oceanside
2 programs
RituximabN/AMonoclonal Antibody1 trial
ObinutuzumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT01613599Completed100Est. Apr 2017
NCT05376319Terminated6Est. May 2024
Chia Tai TianQing Pharmaceutical Group
1 program
Meperizumab injectionPHASE_11 trial
Active Trials
NCT05353179Unknown88Est. Oct 2022
Roche
RocheSTAVANGER NORWAY, Norway
1 program
RituximabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenentechObinutuzumab
Amgenavacopan
Amgenavacopan
Chia Tai TianQing Pharmaceutical GroupMeperizumab injection
Airway TherapeuticsAirway assessment
GenentechRituximab

Clinical Trials (6)

Total enrollment: 239 patients across 6 trials

NCT05376319GenentechObinutuzumab

PR3-AAV Resilient Remission or PRRR

Start: Jun 2023Est. completion: May 20246 patients
Phase 2Terminated
NCT06468826Amgenavacopan

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

Start: Jun 2024Est. completion: Oct 202413 patients
Phase 1Completed
NCT06207682Amgenavacopan

Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin

Start: Jun 2022Est. completion: Aug 202232 patients
Phase 1Completed
NCT05353179Chia Tai TianQing Pharmaceutical GroupMeperizumab injection

Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers

Start: Jun 2022Est. completion: Oct 202288 patients
Phase 1Unknown
NCT03182049Airway TherapeuticsAirway assessment

Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study

Start: Dec 2020Est. completion: May 20230
N/AWithdrawn
NCT01613599GenentechRituximab

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

Start: Jun 2012Est. completion: Apr 2017100 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.